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Abstract
Protein α-helical coiled coil structures are known to induce antibodies able to block critical
functions in different pathogens. In a previous study, a total of 50 proteins of Plasmodium
vivax erythrocytic asexual stages containing α-helical coiled coil structural motifs were iden-
tified in silico, and the corresponding peptides were chemically synthesized. A total of 43
peptides were recognized by naturally acquired antibodies in plasma samples from both
Papua New Guinea (PNG) and Colombian adult donors. In this study, the association
between IgG antibodies to these peptides and clinical immunity was further explored by
measuring total IgG antibody levels to 24 peptides in baseline samples from a longitudinal
study of children aged 1–3 years (n = 164) followed for 16 months. Samples were reactive to
all peptides tested. Eight peptides were recognized by >50% of individuals, whereas only
one peptide had < 20% reactivity. Children infected at baseline were seropositive to 23/24
peptides. No significant association was observed between antibody titers and age or
molecular force of infection, suggesting that antibody levels had already reached an equilib-
rium. There was a strong association between antibody levels to all peptides and protection
against P. vivax clinical episodes during the 16 months follow-up. These results suggest
that the selected coiled coil antigens might be good markers of both exposure and acquired
immunity to P. vivax malaria, and further preclinical investigation should be performed to
determine their potential as P. vivax vaccine antigens.
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Introduction
Plasmodium vivax is the second most important Plasmodium species in terms of epidemiologi-
cal significance, with an estimate of 13.8 million malaria cases globally in 2015, and about half
of the total number of malaria cases occurring outside Africa [1]. Although this parasite has
been classically considered benign, several features make it difficult to control and eliminate.
First, severe and lethal P. vivax malaria cases have been reported [1–4]; second, chloroquine-
resistant strains have recently emerged with at least one case confirmed in 10 countries [1];
third, this parasite species produces hypnozoite-forms that upon periodic reactivation induce
clinical relapses [5, 6], even in individuals who have left endemic regions; and fourth, gameto-
cytes emerge early during the erythrocytic cycle possibly increasing its transmissibility [7, 8].
Because of the difficulty in controlling P. vivax, in areas where the two species coexist its inci-
dence appears to decrease more slowly than that of Plasmodium falciparum [1].
Due to limitations associated with classical malaria control measures, vaccination against
malaria is currently considered a potentially valuable cost-effective complement for malaria
control activities that would significantly contribute to its elimination [9]. During the last 2–3
decades, significant efforts have been invested on developing P. falciparum [10], and more
recently P. vivax vaccines [11]. However, discovery of new potential vaccine candidates is
required. The use of bioinformatics tools has allowed to explore the malaria genome/proteome
databases, and to identify parasite proteins containing specific domains with functional impor-
tance for the parasite that could be immunologically targeted and therefore represent novel
candidate antigens for vaccine development.
Protein α-helical coiled coils are stable structures capable of eliciting antibodies able to
block functional domains in different microorganisms [12–14]. These motifs have been inves-
tigated in influenza virus [13, 15], HIV-1 [12], coronaviruses [14] and malaria parasites [16].
In the case of P. falciparum, 170 α-helical coiled coil motifs have been identified in silico, from
proteins predicted to be in different cellular locations such as the cytoplasm, the nucleus, the
mitochondria, and the peroxysomes and in addition, some of them have trans- membrane seg-
ments. Therefore, synthetic peptides containing these motifs were synthesized, and tested for
their reactivity in serum obtained from adult donors from Burkina Faso, Tanzania and Colom-
bia [17]. The most recognized antigens were selected, and specific human IgG antibodies were
affinity purified and tested in vitro using antibody-dependent inhibition (ADCI) assays, show-
ing that several of them were active in inhibiting in vitro parasite growth [17, 18]. Association
of antibody responses with protection against infection was also observed [18, 19]. In the case
of P. vivax, 43 coiled coils segments with extensive homology to the P. falciparum counterparts
were identified in silico, and the synthesized segments were tested for their reactivity with
serum of individuals from malaria endemic areas [20]. However, due to the lack of P. vivax in
vitro cultures, the functional activity of antibodies elicited to these antigens has not yet been
studied in this parasite species. Similarly, there are no reports on the relationship between anti-
body responses to P. vivax coiled coil antigens and risk of infection or clinical malaria.
In order to explore the association between total IgG antibodies to P. vivax coiled coil seg-
ments (selected based on their antigenicity) and risk of disease, baseline plasma samples from
a cohort of children from Papua New Guinea (PNG) [21] were tested using a multiplexed bead
array assay. In this cohort, 264 children aged 1–3 years were enrolled and actively followed for
up to 16 months to identify factors associated with either risk of or protection from infection
and disease, and the molecular force of blood-stage infection (molFOB) at the individual level
was also assessed [22, 23]. Exposure to P. vivax infections varied greatly (between 0 and 38
clones acquired over the entire study period), and children were found to acquire an average
of 15 new P. vivax blood-stage clones/child/ per year-at-risk [22] estimated as molFOB by high
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resolution genotyping parasites. Despite the high endemicity, the incidence of clinical P. vivax
malaria decreased from approximately 3.5 episodes to 1.5 episodes per year, suggesting acqui-
sition of clinical immunity at young age [21]. In the present study, we identified for the first
time a number of P. vivax coiled coil segments strongly associated with protection against clin-
ical disease. Future studies will help to assess the value of the coiled coil antigens identified
here as markers of acquired immunity or vaccine candidates.
Materials and methods
Study description
Blood samples were collected in 2006, in a rural area near Maprik, East Sepik Province of PNG
[21], including children aged between 1–3 years at enrollment. Children were actively fol-
lowed-up every 2 weeks, with clinical examination for malaria signs and symptoms, and
blood-samples collected every 8 weeks for a period of 16 months. In addition, samples were
collected through passive case detection at health centers. Malaria cases were confirmed by
rapid diagnostic test (RDT) and all samples screened for P. vivax, P. falciparum, P. malariae
and P. ovale by semi-quantitative post-PCR ligase detection reaction-fluorescent microsphere
assay (LDR-FMA). All P. vivax positive samples were genotyped using the markers msp1F3
and MS16 [22] and all P. falciparum positive samples using the marker msp2 [24]. A total of
164 plasma samples collected at baseline, selected from children who completed follow-up
were used to test antibody reactivity against 24 P. vivax coiled coil peptides. P. vivax clinical
malaria episodes were defined as the presence of fever (i.e. axillary temperature >37.5˚C) plus
parasitemia (500 parasites/μL) [21].
Ethics statement
Written informed consent was obtained from all parents or guardians prior to recruitment of
each child. Scientific approval and ethical clearance for the study was obtained from the Medi-
cal Research and Advisory Committee (MRAC) of the Ministry of Health in PNG, the Institu-
tional Review Board (IRB) from PNG Institute of Medical Research (IRB#1005) and the
Human Research Ethics Committee of the Walter and Eliza Hall Institute.
Antigens
Twenty-four coiled coil P. vivax polypeptides of 25 to 57 amino acids, previously described
[20], were selected based on their reactivity with PNG and Colombia IgG antibodies (>30%),
and were used to test the antibody reactivity of PNG samples. Briefly, peptides were synthe-
sized by fluorenylmethoxycarbonyl (F-moc) solid-phase chemistry [25] using an Intavis AG
Bioanalytical synthesizer (Germany) (Table 1). The resulting polypeptides were HPLC-puri-
fied. Purity (>80%) was confirmed by analytic C18 HPLC and mass spectrometry (MALDI-
TOF, Applied Biosystems, Foster City, CA). All reagents were purchased from Fluka (Buchs,
Switzerland) and Novabiochem (Laufelfingen, Switzerland).
Coupling of polypeptides to fluorescent beads
Bio-Plex carboxylated beads (Bio-Rad) were covalently coated with the different coiled coil
polypeptides following the manufacturer’s instructions (Bio-Plex Amine Coupling Kit). Bri-
efly, microspheres (1.25 × 106 beads/mL) were activated with a mixture of N-Hydroxysulfosuc-
cinimide (5mg/mL) and N-(3-Dimethylaminopropyl)-N0-ethylcarbodiimide hydrochloride
(5mg/mL) in H2O for 20 min at room temperature (RT) in the dark. Microspheres were then
washed twice in 250 μL PBS, pH7.4, re-suspended in 500 μL of PBS, pH 7.4, and 1 μg of each
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polypeptide was added. Microspheres were incubated at 4˚C overnight and re-suspended in
500 μL of blocking buffer (PBS + 1% BSA). After further incubation under rotation at RT for
30 minutes, beads were washed with PBS and stored at 4˚C protected from light until use.
Antibody assays
Coupled beads were used to analyze plasma reactivity as described previously [26]. Briefly,
experimental plasma samples and controls were vortexed, centrifuged at maximum speed for
5–10 minutes in a microcentrifuge (Eppendorf), and diluted 1:100 in PBS plus tween 0.1%
(PBT), 50 μL were then added to 50μL of previously mixed beads, and incubated at room tem-
perature and protected from light for 30 min. After washing 3 times with 100 μL of PBT, ali-
quots of 100 μL of R-phycoerythrin conjugated anti-human IgG produced in Donkey (Jackson
Immuno Research) diluted 1:100 were added and incubated for 15 min. Beads were washed
and re-suspended in 125 μL of PBT and read on a Bio-Plex 200. Each plate also contained a
blank (wells containing only beads and PBT). Negative control consisted on a pool of plasma
samples from individuals never exposed to malaria diluted 1:100, and positive control con-
sisted on serial dilutions (1:50–1:25,600) of pooled serum (n = 20) from PNG immune adults.
Statistical analysis
Luminex median fluorescence intensity (MFI) values were converted into arbitrary antibody
units based on the parameters estimated from a standard curve made with dilutions of the
Table 1. Coiled coil peptides protein of origin and sequences.
Peptide Protein MW Sequence Position
No (aa nb) (Plasmodb.org)
Pv5 PVX_003585 2936 IADIKISLEKLKYEVKDKKDCLENV 203–227
Pv12 PVX_003585 5039 YKKELEEKAKIIEDLKDKICTLTNEVMDLKNVKNELAERDSSL 1023–1065
Pv27 PVX_113335 3169 KKQNAEKELSVLKKNYDAMSEEIEEIT 654–680
Pv40 PVX_119385 3634 NETIQRMSNSLLKYEQDIETYQNEVSTLTGK 675–705
Pv42 PVX_087730 3348 NTPDYYKKITTKLQNNINNVEEYINNITNDINILKSSID 154–192
Pv43 PVX_089660 4583 SVDINALNEQVKKLREELNKVTNEYDDFKNKLELLYQK 779–816
Pv45 PVX_123385 4333 KEVKVEVNEVGEEVNEVKEEVNEAKEEVIEKKEEMTE 650–686
Pv52 PVX_123480 3617 VEQVKKEINQINEQININETKITHLRNKIE 176–205
Pv63 PVX_118160 3658 NNEMDETLSKLKKDINKLNEKIQKYDNYVK 207–236
Pv81 PVX_118160 4442 NEMDETLSKLKKDINKLNEKIQKYDNYVKKKRKEID 208–243
Pv82.02 PVX_122740 6721 ETINQIDQKMEEIENNINLALEELKNLDQKILELQASFTCYENEIKQVIKKIEGLEK 862–918
Pv82.03 PVX_091910 6574 IEQLNTKMKNINENSNDSEHVNLAEFELKIAELKEDVNNINNMMKTFEMKFSALEK 471–526
Pv83 PVX_087730 4536 LQNNINNVEEYINNITNDINILKSSIDDERNERIIYNN 166–203
Pv90 PVX_00072 4164 TRRMHSELSDGNKELKKLKKNIVQSDVLNAQLELNI 63–98
Pv92 PVX_114000 4165 PDFDAYNEKLDSISESIDQVKKKIDNLQKEIKVANK 12–47
Pv95 PVX_11745 3512 EKGLKDLNDKIRNYDSIIENQKKELEHLK 145–173
Pv96.01 PVX_124060 6595 VEAVPENAEAAPENADPVHENAEAAPENAEPVHENAE 773–809
Pv96.03 PVX_084385 4482 DVQRIDTINKNISTINDDVDHINSNINNINDNLHKINSH 2051–2089
Pv101 PVX_085155 3554 NKLTEMRRKLKIIDEKVQSVYKAIHAVLNN 314–343
Pv106 PVX_114430 3441 KTIDQLDFEINDLNSKLKNYEKSVSQNKK 673–701
Pv112 PVX_092140 3502 KEMEKIDDQIDRIKNNIKKLNDDLNELTD 1143–1171
Pv121 PVX_094420 3506 LKFNSLKDILSKLLIEMKEHENQYNNLTE 151–179
Pv123 PVX_117855 3455 EKYSLIKEEIKYLNEDLDDLDNSVNVVKK 43–71
Pv145 PVX_100770 3864 MKHVNSLAFLYNEFKNNVEDLEKTYENFLKAL 1 32
https://doi.org/10.1371/journal.pone.0179863.t001
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highly-immune PNG positive control pool, as previously described [27]. Antibody units ran-
ged from 1.95x10-5 (i.e., equivalent to 1:51,200 dilution of the immune pool) to 0.02 (1:50). A
cut-off for positivity was calculated as three standard deviations above the dilution value of
negative controls for each antigen. Individuals were considered sero-positive if the dilutions of
the experimental plasma samples were higher than the cut-off of negative controls cut-off. All
samples were tested in duplicates in two independent experiments. Differences in the preva-
lence of IgG antibodies with age, infection status and exposure were assessed using Fisher’s
exact test. The Spearman rank correlation coefficient was used to investigate the relationship
among antibody responses to the coiled coil antigens. A heat map was created using the corr-
plot function in R. The association between antibody levels to P. vivax coiled coil antigens and
protection against clinical malaria (defined as fever and parasite density >500/μL) [21], as well
as the association between number of recognized antigens and the risk of P. vivax clinical epi-
sodes was assessed using negative binomial GEE models with exchangeable correlation struc-
ture and semi-robust variance estimator [27, 28]. IgG levels were classified into terciles and
analyses done by comparing children with low versus medium and high antibody levels. All
GEE models were adjusted for seasonal trends, village of residency, age and individual differ-
ences in exposure (molFOB). Multivariate analysis with all antigens was also performed using a
backward stepwise regression for the selection of the final model. Analyses were performed
using STATA version 12 (StataCorp) or R version 3.2.1 [29].
Results
Prevalence of IgG antibodies and their association with age, infection
status and village of residency
As expected based on the selection criteria for these 24 peptides, plasma samples collected at
enrollment were reactive to all 24 peptides, with variable frequencies (Table 2). Eight peptides
had the highest percentage of responders with>50% of children reactive (Pv121; Pv82.02
Pv96.01; Pv82.03; Pv95; Pv40; Pv52 and Pv12), whereas only one peptide (Pv90) had< 20%
responders. Overall, 21/164 (13%) samples had antibodies reactive to at least 23 peptides,
whereas 36/164 (22%) samples showed no reaction to any of the peptides tested (Fig 1). All
plasma samples (n = 19) that reacted with all antigens were infected at sampling time, although
there were a few samples (8/36) infected at sampling that did not react with any of the antigens.
There were some differences between Ilahita and Sunuhu villages regarding malaria preva-
lence and age at enrollment [21]. The percentage of infected children at enrollment was higher
in Sunuhu than in Ilahita (33/62; 53% and 39/102; 38% respectively, P = 0.033). For this reason,
reactivity of total IgG from children in these two villages were compared. Children from
Sunuhu were more likely to have IgG antibodies reactive to 22 peptides, although significant
differences were observed only for seven of them (Pv12, Pv63, Pv82.03, Pv95, Pv106, Pv121
and Pv145) (S1 Table). Higher positivity was observed in two hamlets (Ilahita 5 and Sunuhu 1)
for 23 of the 24 antigens (S2 Table).
A positive correlation was observed between antibody positivity to 23 α-helical coiled coil
peptides and P. vivax infection at enrollment (Table 3), with stronger association for peptides
Pv5, Pv83, Pv121, Pv101, Pv52, Pv81, Pv106, Pv145, Pv82.02 and Pv96.03 (P = 0.001–0.010).
Only one peptide (Pv90) had no association with infection status (Table 3). There was no sig-
nificant association between antibody levels to any of the α-helical coiled coil peptides and age
or exposure measured by genotyping during follow-up (S3 and S4 Tables).
Arbitrary antibody units observed to all coiled coil antigens were positively correlated with
each other (Fig 2). The most correlated were Pv82.02-Pv121 (r = 0.99), Pv145-Pv96.01 (r =
0.99), Pv5-Pv96.01 (r = 0.98), and the less correlated with the other antigens was Pv96.
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Association between antibody titer and prospective risk of P. vivax
malaria
During the 16 months of follow-up, children experienced an incidence rate of 1.28 (95% CI
1.08–1.52) clinical malaria episodes. An adjusted GEE model was applied to test whether
responses to the coiled coil antigens were associated with risk of clinical disease. Significantly
lower risk of clinical P. vivax malaria was associated with high levels of IgG for all coiled coil
antigens (Table 4) (adjusted incidence rate ratio (aIRR) ranging from 0.351 to 0.598). When
adjusting for confounders such as age, village of residence, seasonality and individual differ-
ences in exposure, IgG levels to each of coiled coil antigens remained associated with protec-
tion with aIRR ranging from 0.314 to 0.548. Medium and high levels of IgG to 16 coiled coil
fragments were associated with protection. For Pv5, Pv27, Pv42, Pv43, Pv82.02, Pv92 and
Pv96.01, only high (but nor medium) IgG levels were significantly associated with protection
(Fig 3; S5 Table). In general, there was a strong association between increasing antibody levels
and protection for all coiled coil fragments except Pv45 and Pv90. In addition, the association
between the number of recognized antigens and the risk of P. vivax clinical episodes was
assessed, identifying that for each additional recognized antigen there was a reduction in P.
Table 2. Dilution of total IgG response to the different coiled coil peptides.
Antigen Median dilution (IQR) Cut offa Percentage of respondersb (n)
Pv5 3.5E-03 (1.9E-03, 7.1E-03) 4.4E-03 39.6% (65)
Pv12 3.4E-03 (2.1E-03, 6.6E-03) 3.4E-03 50.0% (82)
Pv27 1.0E-03 (6.3E-04, 1.6E-03) 1.3E-03 34.8% (57)
Pv40 4.4E-03 (2.6E-03, 9.6E-03) 4.3E-03 51.2% (84)
Pv42 4.0E-03 (2.5E-03, 7.1E-03) 4.3E-03 46.3% (76)
Pv43 2.2E-03 (1.3E-03, 4.0E-03) 2.5E-03 43.9% (72)
Pv45 3.7E-03 (2.6E-03, 6.8E-03) 4.5E-03 37.2% (61)
Pv52 2.0E-03 (1.3E-03, 3.7E-03) 2.0E-03 50.6% (83)
Pv63 6.9E-04 (4.6E-04, 1.4E-03) 8.4E-04 43.3% (71)
Pv81 2.6E-03 (1.8E-03, 4.9E-03) 3.1E-03 40.2% (66)
Pv82.02 3.6E-03 (2.3E-03, 7.4E-03) 2.8E-03 64.0% (105)
Pv82.03 2.5E-03 (1.4E-03, 4.0E-03) 2.3E-03 53.0% (87)
Pv83 3.2E-03 (2.1E-03, 6.6E-03) 3.6E-03 43.9% (72)
Pv90 3.7E-03 (2.3E-03, 6.6E-03) 8.5E-03 18.9% (31)
Pv92 2.5E-03 (1.6E-03, 4.4E-03) 3.2E-03 35.4% (58)
Pv95 1.0E-03 (6.1E-04, 1.8E-03) 9.7E-04 52.4% (86)
Pv96.01 3.9E-03 (2.2E-03, 8.2E-03) 3.3E-03 56.1% (92)
Pv96.03 7.8E-04 (5.0E-04, 1.7E-03) 8.1E-04 47.0% (77)
Pv101 3.5E-03 (2.0E-03, 6.5E-03) 4.3E-03 40.9% (67)
Pv106 3.8E-03 (2.2E-03, 7.7E-03) 4.1E-03 47.6% (78)
Pv112 5.5E-03 (3.7E-03, 1.4E-02) 5.9E-03 47.6% (78)
Pv121 4.2E-03 (2.7E-03, 8.1E-03) 3.1E-03 64.6% (106)
Pv123 5.0E-03 (3.2E-03, 1.0E-02) 5.5E-03 43.3% (71)
Pv145 4.5E-03 (2.6E-03, 1.0E-02) 4.5E-03 49.4% (81)
aThe cut-off for positivity was determined as the mean+3 standard deviations of negative control plasma
samples (Australian residents) included in each assay.
bResponders defined as individuals whose plasma dilution was above the cut-off for positivity for a given
antigen.
Bold peptides correspond to those reacting with >50% of the tested sera
https://doi.org/10.1371/journal.pone.0179863.t002
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vivax clinical risk (aIRR: 0.970, P<0.001, 95% CI: 0.953–0.987). Finally, when multivariate
analyses and backward stepwise regression were performed, only antibody levels to Pv95
(aIRR(multi) = 0.35, p<0.001, 95% CI: 0.209, 0.604) remained significantly associated with a
reduced risk of P. vivax clinical disease.
IgG responses to any P. vivax coiled coil antigens were not associated with protection
against P. falciparum clinical episodes, suggesting that these associations observed are species-
specific (S6 Table).
Discussion
Repeated exposure to malaria infection results in development of clinical immunity, which is a
multifactorial process where antibodies play a major role [30]. Both polyclonal and monoclo-
nal antibodies have shown the potential to prevent malaria infections or to completely clear
parasitemia [31, 32]. Plasmodium coiled coil domains have been previously been proposed as
potential targets for human malaria vaccine development, since such domains fold into stable
structures that are capable of eliciting antibodies reactive against parasite functional epitopes,
and are in general non- or little polymorphic [17, 33].
Down selection of P. vivax antigens could represent a challenge due to the technical difficul-
ties and limitations presented by the lack of an in vitro culture system for this parasite species.
Previously, naturally acquired antibodies to the P. vivax merozoite surface protein 1 (Pv-
MSP1) [34] and binding-inhibitory antibodies response to P. vivax Duffy binding protein
(PvDBP) [35] have been associated with reduced risk of P. vivax clinical manifestations in indi-
viduals from the Brazilian Amazon region. In addition, the contribution of antibody titers to
the acquisition of protection against clinical disease has been assessed in a cohort of children
from PNG. In this population, immunity against clinical P. vivax malaria was acquired at a
young age with a 3-fold decrease in episodes between the ages of 1 and 4 years [21, 36, 37]. In
previous studies using this cohort, it have been demonstrated a strong association between
specific IgG to merozoite surface proteins PvMSP3a, PvMSP9, [28], three novel merozoite pro-
teins (PVX_081550, P12 and P41, [27]) as well as the reticulocyte specific binder RBP2b and
RBP1a and clinical protection [38].
Fig 1. Positivity to different α-helical coiled coil peptides. Data are plotted as the percentage of
individuals who are antibody positive for 0–24 of the antigens tested.
https://doi.org/10.1371/journal.pone.0179863.g001
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Here, by using the same PNG cohort we demonstrated that P. vivax coiled coil antigens are
also targeted by natural acquired immunity and reactive with plasma from all Plasmodium spe-
cies including both P. vivax and P. falciparum exposed and infected children. This antibody
reactivity observed at recruitment time was associated with acquisition of protective immunity
against only P. vivax clinical disease. It was found that children with high antibody levels to all
the coiled coil antigens had 2–3 fold lower risk of clinical P. vivax malaria during follow-up. In
addition, a positive association between the number of recognized antigens and protection
against P. vivax clinical episodes was also found. This corroborates the role of acquired immu-
nity as explanation for the decrease in incidence of P. vivax clinical disease with an increase in
age, despite constant exposure [21, 36, 37]. Multivariate analysis revealed antibody levels to
Pv95 as the only antigen significantly associated with a reduced risk of clinical malaria, which
may indicate that this fragment is particularly targeted by natural immunity or a good marker
of immunity. Given the high correlation between antibody responses to the coiled coil frag-
ments, it is difficult to differentiate co-acquisition of antibodies from cross reactivity in multi-
variate analyses. This correlation is observed even though most of the antigens are derived
from completely different proteins with limited sequence homology among the peptides,
Table 3. Reactivity of antibodies at enrollment based on status of infection.
Antigen Infecteda (%) Non-infected (%) OR P-valued
Positiveb Negativec Positiveb Negativec
Pv5 39 (24) 33 (20) 26 (16) 66 (40) 3.00 0.001
Pv12 43 (26) 29 (18) 39 (24) 53 (32) 2.02 0.028
Pv27 32 (20) 40 (24) 25 (15) 67 (41) 2.14 0.021
Pv40 44 (27) 28 (17) 40 (24) 52 (32) 2.04 0.025
Pv42 41 (25) 31 (19) 35 (21) 57 (35) 2.15 0.016
Pv43 39 (24) 33 (20) 33 (20) 59 (36) 2.11 0.019
Pv45 32 (20) 40 (24) 29 (18) 63 (38) 1.74 0.089
Pv52 46 (28) 26 (16) 37 (23) 55 (34) 2.63 0.003
Pv63 38 (23) 34 (21) 33 (20) 59 (36) 2.00 0.030
Pv81 38 (23) 34 (21) 28 (17) 64 (39) 2.55 0.004
Pv82.02 54 (33) 18 (11) 51 (31) 41 (25) 2.41 0.010
Pv82.03 46 (28) 26 (16) 41 (25) 51 (31) 2.20 0.014
Pv83 42 (26) 30 (18) 30 (18) 62 (38) 2.89 0.001
Pv90 15 (9) 57 (35) 16 (10) 76 (46) 1.25 0.576
Pv92 33 (20) 39 (24) 25 (15) 67 (41) 2.27 0.013
Pv95 44 (27) 28 (17) 42 (26) 50 (30) 1.87 0.049
Pv96.01 47 (29) 25 (15) 45 (27) 47 (29) 1.96 0.036
Pv96.03 42 (26) 30 (18) 35 (21) 57 (35) 2.28 0.010
Pv101 39 (24) 33 (20) 28 (17) 64 (39) 2.70 0.002
Pv106 43 (26) 29 (18) 35 (21) 57 (35) 2.41 0.006
Pv112 41 (25) 31 (19) 37 (23) 55 (34) 1.97 0.033
Pv121 56 (34) 16 (10) 50 (30) 42 (26) 2.94 0.002
Pv123 38 (23) 34 (21) 33 (20) 59 (36) 2.00 0.030
Pv145 44 (27) 28 (17) 37 (23) 55 (34) 2.34 0.008
aP. vivax infection status was determined by post-PCR LDR-FMA at enrollment.
bSamples positive for infection at enrollment (n = 72)
cSamples negative for P. vivax infection at enrollment (n = 92)
dP values0.05 were considered significant. P-value calculated by Fisher’s exact test
https://doi.org/10.1371/journal.pone.0179863.t003
Natural immune response to P. vivax coiled coil motif and association with malaria risk
PLOS ONE | https://doi.org/10.1371/journal.pone.0179863 June 26, 2017 8 / 14
except for Pv63 and Pv81 that show high level of homology (98%) [20]. Although cross-reactiv-
ity is likely, 24 peptides were tested using 164 individuals samples and for several individual
donors a unique set of peptides was recognized (with the only exceptions for those that recog-
nized none or most of the peptides) (S1 Fig). In addition, by using affinity-purified antibodies
no cross-reactivity was observed between the P. falciparum protein sequences orthologous to
P. vivax [17]. Therefore, further research in different populations exposed to P. vivax is how-
ever warranted to confirm this association.
Serum samples from PNG were reactive to all P. vivax coiled coil peptides tested, and in
most cases, prevalence was comparable to that previously observed using adult’s sera from a
different PNG region [20]. Moreover, about 25% of children were infected at baseline, and
their plasma showed reactivity to most of the antigens. These data suggest that some of these
antigens could be markers of recent exposure.
Increased reactivity to P. vivax coiled coil peptides was observed in children living in vil-
lages where exposure to P. falciparum is higher (Ilahita 5 and Sunuhu 1) [21]. This observation
could be explained by the high homology observed between the P. falciparum and P. vivax
Fig 2. Heat map representation of correlation of antibody response between coiled coil antigens. The heat map
colors correspond to correlations grading from -1 (negative correlation, red), no correlation (white) to 1 (positive
correlation, blue).
https://doi.org/10.1371/journal.pone.0179863.g002
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coiled coil antigens [20]. Indeed, cross-reactivity to P. vivax peptides was observed in sera
from African donors (Supplementary results, S7 Table). However, in the PNG cohort there
was no association between antibody response to P. vivax antigens and protection from clinical
P. falciparum malaria. Even though the numbers of clinical episodes with P. falciparum and P.
vivax were similar, there was no evidence of acquisition of clinical immunity to P. falciparum
in the age group covered by this cohort [21]. These results correlate with previous studies
using this study cohort, where no significant associations was observed between antibody
responses to any of the P. vivax proteins and risk of P. falciparum clinical episodes [27, 28].
This could be explained by differences in the age of immunity acquisition, the decrease in risk
of infection to P. falciparum is only seen in adolescence and early adulthood [39].
Data presented here, along with those previously published [20], point to the 24 selected
coiled coil P. vivax antigens as good markers of acquired immunity to P. vivax and to an
important potential source of malaria vaccine candidates. Further insight may be provided by
studies in animal models i.e. primates to determine experimentally the protective efficacy of
these antibodies against P. vivax blood infection as well as to further assess the reactivity
between peptides and select the most promising candidates for vaccine development.
Table 4. Association between IgG levels to P. vivax antigens and protection against clinical malaria (parasite density >500/μl of blood).
Antigen aIRR b95% CI cP-value daIRR b95% CI cP-value
Pv5 0.398 (0.250, 0.633) <0.001 0.385 (0.249, 0.596) <0.001
Pv12 0.427 (0.248, 0.734) 0.0021 0.385 (0.237, 0.625) <0.001
Pv27 0.395 (0.208, 0.749) 0.0044 0.414 (0.231, 0.740) <0.001
Pv40 0.425 (0.275, 0.657) <0.001 0.402 (0.262, 0.618) <0.001
Pv42 0.399 (0.231, 0.689) <0.001 0.377 (0.223, 0.639) <0.001
Pv43 0.48 (0.303, 0.761) 0.0018 0.441 (0.286, 0.680) <0.001
Pv45 0.451 (0.256, 0.794) 0.0058 0.416 (0.252, 0.686) <0.001
Pv52 0.404 (0.240, 0.681) <0.001 0.397 (0.250, 0.631) <0.001
Pv63 0.538 (0.288, 1.007) 0.0525 0.479 (0.319, 0.719) <0.001
Pv81 0.441 (0.272, 0.715) <0.001 0.405 (0.252, 0.650) <0.001
Pv82.02 0.374 (0.234, 0.597) <0.001 0.366 (0.230, 0.581) <0.001
Pv82.03 0.419 (0.255, 0.690) <0.001 0.413 (0.261, 0.653) <0.001
Pv83 0.396 (0.249, 0.630) <0.001 0.39 (0.246, 0.619) <0.001
Pv90 0.598 (0.357, 1.000) 0.05 0.548 (0.356, 0.844) 0.0063
Pv92 0.429 (0.270, 0.680) <0.001 0.411 (0.268, 0.630) <0.001
Pv95 0.375 (0.219, 0.644) <0.001 0.338 (0.206, 0.556) <0.001
Pv96.01 0.425 (0.270, 0.669) <0.001 0.401 (0.258, 0.623) <0.001
Pv96.03 0.475 (0.304, 0.743) 0.0011 0.468 (0.305, 0.719) <0.001
Pv101 0.454 (0.276, 0.749) 0.0020 0.415 (0.259, 0.665) <0.001
Pv106 0.526 (0.307, 0.901) 0.0194 0.479 (0.299, 0.766) 0.0021
Pv112 0.351 (0.209, 0.587) <0.001 0.314 (0.190, 0.521) <0.001
Pv121 0.384 (0.241, 0.610) <0.001 0.372 (0.236, 0.586) <0.001
Pv123 0.475 (0.293, 0.770) 0.0025 0.43 (0.271, 0.680) <0.001
Pv145 0.416 (0.266, 0.649) <0.001 0.377 (0.242, 0.588) <0.001
aIRRs incidence rate ratio, are derived from crude negative binomial GEE models. GEE, generalized estimating equation.
b95% CI, 95% confidence interval.
cP-values 0.05 were considered statistically significant.
daIRRs adjusted incidence rate ratios, are negative binomial GEE model estimates adjusted for age, village of residence, seasonality, and individual
differences in exposure (molFOB).
https://doi.org/10.1371/journal.pone.0179863.t004
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S1 Fig. Reactivity pattern of sera samples against the P. vivax coiled coil fragments.
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S1 Table. Prevalence of responders to P. vivax coiled coil fragments in young children
from Ilahita and Sunuhu villages.
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Fig 3. IgG to P. vivax coiled coil antigens and risk of clinical malaria in PNG children. Data are plotted as incidence rate ratios and 95%
confidence intervals, adjusted for exposure (molFOB), age, season, and village of residency. P values <0.05 were considered significant.
*P > 0.05 to 0.01; ** P > 0.01 to 0.001; ***P < 0.001.
https://doi.org/10.1371/journal.pone.0179863.g003
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